Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6100389

Title:Polynucleotides encoding a human chemotactic protein
Inventors:Li, Haodong; Gaithersburg, MD, USA
Summary:Described herein is a chemotactic polynucleotide, methods and uses thereof. The invention relates to a human chemotactic polypeptide, the DNA and RNA encoding it, and a procedure for producing such a polypeptide by recombinant techniques. Further disclosed are polypeptide antagonists and diagnostic assays for identifying mutations in nucleic acid sequences encoding a polypeptide. Therapeutic applications include uses in stem cell mobilization, myeloprotection, neuronal protection, wound healing, the treatment of parasitic infection, the treatment of tumors, the regulation of hematopoiesis, and in the diagnosis of conditions associated with the expression of the chemotactic polypeptide.
Abstract:A human chemotactic polypeptide, DNA (RNA) encoding it, and a procedure for producing such a polypeptide by recombinant techniques are disclosed. Also disclosed are methods of using the polypeptide for a number of purposes, including: stem cell mobilization, myeloprotection, neuronal protection, treating tumors, wound healing, treating parasitic infection, and regulating hematopoiesis. Also disclosed are polypeptide antagonists and diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6100389
Application Number:US1998000044855
Date Filed:20/03/1998
Date Published:08/08/2000
Assignee:Human Genome Sciences, Inc., Rockville, MD, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021